The mission of the biostatistics shared resource (BSR) is to serve as a focal point for University of Virginia Cancer Center (UVACC) members to obtain assistance in the design, management and analysis of their studies. The services provided by this resource include: 1) Biostatistical collaboration and consultation in the design of clinical trials, observational studies and laboratory studies. An appropriate statistical design is necessary if the research is to be successful in fulfilling the scientific objectives. 2) Statistical expertise in data analysis. The specific methods employed depend on the randomization or sampling design of the particular project and on the scale (binary, ordered categorical, or continuous) of the outcome variable being investigated. Statistical data analyses are performed using both packaged and special purpose computer programs. 3) Scientific review, quality control, and data and safety study monitoring for clinical trials. Involvement throughout the entire process is important to ensure that valid designs are planned as well as followed. 4) Education; through formal and informal seminars, courses and lectures. Education defines the academic environment for which all members participate. 5) Development of statistical methodology, computer programs and infrastructure necessary for meeting the scientific objectives of specific research studies. Advances in research can require the development of new statistical methodologies to achieve the research goals. The BSR enriches research at the UVACC by providing high quality design and analyses for basic, clinical and translational studies and unique expertise in novel designs in early phase trials. The BSR provides statistical knowledge in all phases of clinical research, including scientific and safety review, data quality, and monitoring of on-going trials. Through its educational efforts, the BSR promotes an understanding of statistical principles that enhances research efforts in the UVACC. We have increased the breadth of our collaborative skills to include new areas of expertise including joint modeling of longitudinal assessments and time-to-event endpoints, analyses to assess synergy in pre-clinical studies, and methods for tumor outgrowth studies while augmenting our core expertise in early phase trial design.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-27
Application #
9420539
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
27
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Hao, Yi; Bjerke, Glen A; Pietrzak, Karolina et al. (2018) TGF? signaling limits lineage plasticity in prostate cancer. PLoS Genet 14:e1007409
Obeid, Joseph M; Kunk, Paul R; Zaydfudim, Victor M et al. (2018) Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 67:161-174
Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679

Showing the most recent 10 out of 539 publications